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ORIGINAL RESEARCHABSTRACT
The objective of this study was to assess the ability of
prophylactically administered gallium maltolate (GaM)
to inhibit growth or kill Rhodococcus equi within murine
macrophage-like (J774A.1) cells. Cells were treated
with three different doses of GaM or a single dose of
maltol (equivalent to the concentration present in the
highest dose of GaM studied); they were then infected
with virulent R. equi and incubated. Quantitative cul-
tures of R. equi from lysed macrophages were obtained
at 0, 24, 48, and 72 hours. All GaM dosages resulted in
significant reductions of intracellular R. equi compared
with untreated control cells, and a dose–response effect
was evident. Maltol treatment alone had no significant
effect on intracellular R. equi concentrations compared
with untreated control cells. Results suggest the poten-
tial usefulness of gallium maltolate for the prevention or
control of R. equi infections.
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INTRODUCTION
Rhodococcus equi is an opportunistic bacterium that sur-
vives and replicates in macrophages. It causes severe
disease, principally pneumonia characterized by pyogranu-
lomatous lesions, in foals1 and immunodeficient people.2
Most foals likely become infected within the first few
days of life,3 when they may have immature or ineffective
innate immune responses.4-7 Effective vaccines are not
available, and R. equi hyperimmune plasma, the only pro-
phylactic strategy proven to significantly reduce the inci-
dence and severity of this disease,8-10 has important
limitations.1
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microorganisms, including R. equi,11 because of its re-
quirement in various metabolic and DNA-synthetic path-
ways.12 Ferric iron sequestration by the host’s iron
transport proteins, primarily transferrin, is an innate
defense mechanism to limit the availability of iron to path-
ogenic microbes. Rhodococcus equi, however, can use trans-
ferrin-bound iron, thereby circumventing this defense
mechanism.11
Gallium (Ga) is a trivalent semimetallic element that
mimics Fe3þ: it binds to ferric sites on transferrin, is ac-
quired from transferrin by certain bacteria, and is preferen-
tially taken up by mononuclear phagocytes at sites of
inflammation.12,13 Unlike Fe3þ, however, Ga is not reduc-
ible to a divalent form under physiologic conditions. This
precludes its participation in crucial bacterial iron-depen-
dent DNA-synthetic pathways, thereby accounting for gal-
lium’s antimicrobial activity. Experimentally, Ga inhibits
various microorganisms, including R. equi, by exploiting
their iron dependency.12-15 Gallium (as gallium nitrate) is
bactericidal for extracellular R. equi because of interference
with bacterial iron utilization.14
Gallium maltolate (GaM), a coordination complex of
gallium and maltol, provides high Ga bioavailability after
oral administration in humans and a variety of animal spe-
cies, including newborn foals,16 and it has not been associ-
ated with significant toxicity or gastrointestinal irritation.17
Prophylactic intragastric administration of GaM to experi-
mentally infected mice reduced their R. equi tissue bur-
dens.14 The purpose of this study was to assess the ability
of prophylactically administered GaM to inhibit growth
or kill virulent R. equi within macrophages.
MATERIALS AND METHODS
Bacteria
Virulent R. equi (ATCC 33701) were grown in R. equi
minimal medium11 for 24 hours at 378C with rotation
(80 rpm), centrifuged at 1,500g, washed with RPMI-
1640 (Invitrogen Corp., San Diego, CA), suspended in
aliquots of RPMI-1640 with 15% glycerol, and stored
at 808C. For each experiment, bacteria were thawed at
378C, centrifuged at 2,000g for 10 minutes, and washed
twice with Caþþ- and Mgþþ-free phosphate-buffered341
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terial pellets were resuspended in a volume of complete
Dulbecco’s modified Eagle’s medium (CDMEM) (Invi-
trogen Corp., San Diego, CA), plus 10% fresh-frozen
and filter-sterilized equine serum as a source of comple-
ment, R. equi antibody, and transferrin (CDMEM-EqFF)
equal to that of the original aliquots. After 1 hour incuba-
tion at 378C with rotation for opsonization, bacterial con-
centrations were adjusted spectrophotometrically at 600
nm to approximately 1 106/ml. Bacterial concentrations
were assessed by duplicate plate counts of 10-fold serial di-
lutions on trypticase soy agar with 10% sheep red blood cells
(Becton-Dickinson Microbiology Systems, Cockeysville,
MD) and recorded as colony-forming units (CFU)/ml.
Macrophages
Murine macrophage-like J774A.1 cells were propagated in
75 cm2 tissue culture flasks (BD Falcon, Bedford, MA)
with CDMEM þ 200 mM glutamine, 0.075% NaHCO3,
1% essential amino acids, and 10% equine serum (Invitro-
gen Corp., San Diego, CA) (CDMEM-Eq) at 378C in 5%
CO2. Cells were washed once with PBS-free to remove
and discard unattached cells. Remaining cells were de-
tached by incubating in PBS-free for 30 minutes at 378C
in 5% CO2, and scraping. Cell suspensions were trans-
ferred to tubes and centrifuged 10 minutes at 1,100g.
Supernatants were discarded, cells resuspended in
CDMEM-EqFF, and cell counts and viability determined
by hemacytometer and trypan blue dye-exclusion, respec-
tively. Concentrations of viable J774A.1 cells were adjusted
to approximately 1 105 cells/ml with CDMEM-Eq. One
milliliter cell suspension was seeded into each well of
24-well poly-D-lysine plates (BD Biosciences, Bedford,
MA), in triplicate, for each of five GaM and three maltol
treatment experiments and for four incubation times
(ie, 0, 24, 48, and 72 hours).
Treatment and Infection
Gallium maltolate treatment groups were: (1) cells only;
and (2) cells þ 10, 50, or 75 mM GaM (Norac Inc., Azusa,
CA). Maltol groups were: (1) cells only; and (2) cellsþ 225
mM maltol (Sigma Chemical Co., St. Louis, MO) (a con-
centration equivalent to that contained in 75 mM GaM).
Cells were incubated overnight at 378C in 5% CO2, and
R. equi were then added to each well at a multiplicity of in-
fection of 1 (ie, 1 bacterium per macrophage). The cells
were continuously exposed to their assigned concentra-
tions of GaM or maltol before and after infection with R.
equi. Cells were incubated 1 hour at 378C to permit bacte-
rial phagocytosis, washed with CDMEM-EqFF to remove
unattached bacteria, and re-suspended in CDMEM-EqFF
containing 10 mM gentamicin to control remaining extra-
cellular bacteria, as previously described.18
Bacterial Quantification
At 0, 24, 48, and 72 hours postinfection, medium was
removed, centrifuged at 2,000g for 10 minutes, and thesupernatant discarded. Adherent cells were lysed by adding
500 ml 0.05% Tween 20 in ddH2O (Sigma Chemical Co.,
St. Louis, MO) to each well and pipetted vigorously. Cell
lysates were combined and vortexed with pelleted nonad-
herent cells for 1 minute to complete lysing, and sonicated
(Ultrasonic Cleaner) (American Scientific Products,
McGaw Park, IL) 5 minutes to minimize clumping of R.
equi (S. Giguere, University of Florida, personal communi-
cation). Lysate bacterial concentrations were assessed by
duplicate plate counts of 10-fold serial dilutions on trypti-
case soy agar with 10% sheep red blood cells, and recorded
as CFU/ml.
Data Analysis
The outcome of interest was the extent to which GaM
influenced intracellular concentrations of R. equi over
time, relative to the initial (baseline) concentration.
Thus, the dependent variable in analyses was the ratio of
concentration of R. equi at a given experiment, time, and
treatment relative to the corresponding initial concen-
tration, indicating the change in concentration over time
relative to baseline: ratio values significantly less than 1
indicated reduced concentrations of R. equi relative to
time 0, and ratio values significantly greater than 1 indi-
cated increased concentrations of R. equi relative to time
0. Because the ratio data were not normally distributed,
ratios were transformed logarithmically (base 10). Linear
mixed-effects models were used for analysis,19 where ex-
periment was modeled as a random effect, and time, treat-
ment, and their interaction term were modeled as fixed
effects. Post hoc testing was performed using the method
of Sidak.20 A significance level of P % .05 was used.
RESULTS
On the basis of microscopic assessments, there were no ap-
parent differences in J774A.1 cell morphology or growth
characteristics within groups and among groups at any
time. The concentration ratios of R. equi varied signifi-
cantly as a function of time for all groups, including con-
trols (Fig. 1). By 48 hours, all three GaM treatment
groups were significantly different from untreated con-
trols, but not from each other. Ratios were inversely pro-
portional to treatment dose at 48 hours and 72 hours
(Fig. 1), although the differences were not significant.
The untreated controls had significantly higher concentra-
tions of R. equi after 24 hours relative to time 0, and this
difference was maintained through 72 hours. For the
GaM-treated groups, there appeared to be some increase
in R. equi relative to baseline after 24 hours, although
this increase was only significant for the 10-mM dose. Con-
centrations of R. equi then began to decrease among GaM-
treated cells, and were significantly different from baseline
for the 50-mM and 75-mM doses but not for the 10-mM
dose; ratios for all three GaM treatment groups were signif-
icantly lower at 72 hours than at 24 hours. There was no
significant (P R .373) difference in R. equi concentrations
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sampling time, indicating that the GaM-elicited response
was not attributable to maltol alone (Fig. 2).
DISCUSSION
Rhodococcus equi is a facultative intracellular pathogen
whose virulence appears to be related to its ability to survive
in macrophages by inhibiting events associated with phag-
olysosome acidification or other late endosomal reac-
tions.21 Thus, antimicrobial strategies to prevent or
control R. equi infections must be able to target this path-
ogen intracellularly. These data provide the first evidence
that GaM significantly reduces the intracellular concentra-
tion of a pathogen, viz., R. equi (Fig. 1) and that this neg-
ative impact on intracellular growth and viability of R. equi
is not attributable to maltol (Fig. 2). In addition, they fur-
ther substantiate a potential role for GaM-prophylaxis in
the control of R. equi foal pneumonia.
On the basis that: (1) prophylactic administration of
gallium maltolate to newborn foals has been proposed
as a potential strategy for the control of R. equi
Figure 1. Mean ratios of R. equi within J774A.1
macrophage cells after 0, 24, 48, and 72 hours’ exposure
to gallium maltolate (GaM), to concentrations at
0 hours (‘‘fold change’’). Error bars indicate 95%
confidence intervals. Values with different numbers
above the upper confidence bounds represent
significant (P < .05) differences among GaM dosages at
given time periods. Values with different letters below
the lower confidence bounds represent significant (P <
.05) differences among times at given GaM dosages.pneumonia22; (2) foal tissues would be continuously
exposed to transferrin-bound GaM throughout the pro-
posed period of chemoprophylaxis; and (3) transferrin-
bound gallium is preferentially taken up by activated
phagocytic cells and accumulates at sites of infection
and granulomatous lesions,12,23 macrophages in this
study were continuously exposed to GaM or maltol be-
fore and after infection with R. equi.
The effectiveness of gallium to control R. equi is depen-
dent on its concentration in infected tissues, principally
macrophages (the target cell for R. equi),18 rather than in
blood serum, or in the case of this study, tissue culture me-
dia. In a previous study involving prophylactic GaM treat-
ment of mice experimentally infected with R. equi, there
was a reduction in tissue concentrations of R. equi com-
pared with untreated controls.14 This reduction was not
statistically significant; however, extrapolation of serum
Ga concentration and tissue R. equi concentration data
indicated that a serum Ga concentration of 700 ng/ml
would reduce R. equi tissue burdens by approximately
90%.14 The lowest GaM concentration used in the current
study (ie, 10 mM) contained 697 ng/ml elemental Ga. This
concentration of GaM killed significant numbers of intra-
cellular R. equi, with even greater numbers of bacteria be-
ing killed at higher GaM concentrations. This is of major
clinical importance, because relatively low Ga serum
Figure 2. Mean ratios of R. equi within J774A.1
macrophage cells after 0, 24, 48, and 72 hours’ exposure
to maltol, to concentrations at 0 hours (‘‘fold change’’).
Error bars indicate 95% confidence intervals. There were
no significant effects of maltol treatment at any time.
For a given maltol dose, values with different letters
below the lower bound of the 95% confidence interval
represent significant (P< .05) differences among times.
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infected tissues (well known from 67Ga scans used to
diagnose sites of infection12). A recent study by these
investigators confirmed that Ga serum concentrations of
700 ng/ml are readily and safely achievable in neonatal
foals after enteral administration of GaM.16
Murine macrophage-like J774A.1 cells were used in this
study on the basis that virulent R. equi (ATCC 33701)
survive and multiply in those cells18 in a manner similar
to that observed in murine peritoneal macrophages and
equine alveolar macrophages.18 Some growth of R. equi
within the J774A.1 cells was therefore anticipated, and
we hypothesized that GaM would negatively influence
that growth. As illustrated, R. equi concentrations in con-
trol cells in the GaM study (Fig. 1) and both control and
treated cells in the maltol study (Fig. 2) exhibited similar
temporal patterns: an increase over baseline that was
greatest at 24 hours, with gradual reductions at 48 and
72 hours. As hypothesized, the GaM had a significantly
negative impact on the intracellular growth and viability
of R. equi across times (Fig. 1), and this negative influ-
ence was not attributable to maltol (Fig. 2). Because vir-
ulent R. equi can destroy infected macrophages,24 the
possibility that some extracellular bacteria released from
extirpated cells may have been killed by gentamicin or
GaM in the media cannot be ruled out. This may account
for the slight reduction in R. equi concentrations in both
sets of control cells and maltol-treated cells after 24 hours,
and reductions of similar magnitude in GaM-treated cells
(Figs. 1 and 2). Alternatively, sonication of cell lysates
may not have dissipated all of the clumped R. equi. In
that case, each clump of R. equi would have produced
a single colony when quantitatively cultured, thereby arti-
ficially lowering bacterial counts as previously described.18
On the basis of pharmacokinetic studies in foals16 and in
vivo studies in mice,14 daily enteral administration of GaM
for the first weeks of a foal’s life may provide adequate pro-
tection against early infection by preventing invading R.
equi from growing to overwhelming numbers before in-
nate immune responses sufficiently mature or specific adap-
tive immunity can be established to control infections.
This, in turn, could substantially reduce the incidence of
disease on farms on which R. equi foal pneumonia is en-
demic. In addition, GaM used alone or in conjunction
with standard antibiotic protocols may be effective for
the treatment of established infections.
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Lüehrmann J, Takai S, et al. Necrotic death of Rhodococcus equi-
infected macrophages is regulated by virulence-associated plasmids.
Infect Immun 2004;72:853–862.
